Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Retrospective Study of Patients Switched from Tablet Formulations to a Gel Cap Formulation of Levothyroxine: Results of the CONTROL Switch Study.

Ernst FR, Sandulli W, Elmor R, Welstead J, Sterman AB, Lavan M.

Drugs R D. 2017 Mar;17(1):103-115. doi: 10.1007/s40268-016-0150-z.

2.

The Economic Impact of Levothyroxine Dose Adjustments: the CONTROL HE Study.

Ernst FR, Barr P, Elmor R, Sandulli W, Thevathasan L, Sterman AB, Goldenberg J, Vora K.

Clin Drug Investig. 2017 Jan;37(1):71-83. doi: 10.1007/s40261-016-0462-3.

3.

Comorbidities, Concomitant Medications, and Diet as Factors Affecting Levothyroxine Therapy: Results of the CONTROL Surveillance Project.

McMillan M, Rotenberg KS, Vora K, Sterman AB, Thevathasan L, Ryan MF, Mehra M, Sandulli W.

Drugs R D. 2016 Mar;16(1):53-68. doi: 10.1007/s40268-015-0116-6.

4.

Acute stroke therapy trials: problems in patient accrual.

LaRue LJ, Alter M, Traven ND, Sterman AB, Sobel E, Kleiner J.

Stroke. 1988 Aug;19(8):950-4.

PMID:
3400106
5.

Acute stroke therapy trials: an introduction to recurring design issues.

Sterman AB, Furlan AJ, Pessin M, Kase C, Caplan L, Williams G.

Stroke. 1987 Mar-Apr;18(2):524-7.

PMID:
3564113
6.

Clinical presentation of multi-infarct delirium.

Balter RA, Fricchione G, Sterman AB.

Psychosomatics. 1986 Jun;27(6):461-2. No abstract available.

PMID:
3737836
7.

Focal neurologic symptoms in panic attacks.

Coyle PK, Sterman AB.

Am J Psychiatry. 1986 May;143(5):648-9.

PMID:
3963257
8.

Disseminated abnormalities of cardiovascular autonomic functions in multiple sclerosis.

Sterman AB, Coyle PK, Panasci DJ, Grimson R.

Neurology. 1985 Nov;35(11):1665-8.

PMID:
4058759
9.

Cell body responses to axonal injury: traumatic axotomy versus toxic neuropathy.

Sterman AB, Delannoy MR.

Exp Neurol. 1985 Aug;89(2):408-19.

PMID:
4018210
10.

Humoral abnormalities in three patients with idiopathic chronic polyneuropathy.

Coyle PK, Schutzer SE, Sterman AB, Peress N, Miller F.

N Y State J Med. 1985 Jun;85(6):248-50. No abstract available.

PMID:
3895061
11.

2,5-Hexanedione and acrylamide produce reorganization of motoneuron perikarya.

Sterman AB, Sposito N.

Neuropathol Appl Neurobiol. 1985 May-Jun;11(3):201-12.

PMID:
4033873
12.

Toxic neuropathy.

Sterman AB.

Mayo Clin Proc. 1985 Jan;60(1):59-61. No abstract available.

PMID:
2981376
13.

The pathology of toxic axonal neuropathy: a clinical-experimental link.

Sterman AB.

Neurobehav Toxicol Teratol. 1984 Nov-Dec;6(6):463-6.

PMID:
6531051
14.
15.

Acrylamide-induced remodelling of perikarya in rat superior cervical ganglia.

Sterman AB.

Neuropathol Appl Neurobiol. 1984 May-Jun;10(3):221-34.

PMID:
6738806
16.

Motoneuron axosomatic synapses are altered in axonopathy.

Sterman AB, Sposito N.

J Neuropathol Exp Neurol. 1984 Mar;43(2):201-9.

PMID:
6707705
17.

Does pyruvate prevent acrylamide neurotoxicity? Implications for disease pathogenesis.

Sterman AB, Panasci DJ, Persons W.

Exp Neurol. 1983 Oct;82(1):148-58.

PMID:
6628605
18.

Evaluating human neurotoxicity of the pesticide aldicarb: when man becomes the experimental animal.

Sterman AB, Varma A.

Neurobehav Toxicol Teratol. 1983 Sep-Oct;5(5):493-5. No abstract available.

PMID:
6320022
19.

Subacute toxic delirium following nitrous oxide abuse.

Sterman AB, Coyle PK.

Arch Neurol. 1983 Jul;40(7):446-7.

PMID:
6860185
20.

Does neurotoxic conditioning accelerate nerve regeneration?

Sterman AB.

Exp Neurol. 1983 Jun;80(3):726-31.

PMID:
6852164
21.
22.

Autonomic-cardiovascular dysfunction accompanies sensory-motor impairment during acrylamide intoxication.

Sterman AB, Panasci DJ, Sheppard RC.

Neurotoxicology. 1983 Spring;4(1):45-52.

PMID:
6683826
23.

A correlative neurobehavioral-morphological model of acrylamide neuropathy.

Sterman AB, Sheppard RC.

Neurobehav Toxicol Teratol. 1983 Jan-Feb;5(1):151-9.

PMID:
6304547
24.

Demyelinating neuropathy accompanying Lyme disease.

Sterman AB, Nelson S, Barclay P.

Neurology. 1982 Nov;32(11):1302-5. No abstract available.

PMID:
6890169
25.
26.

A neurobehavioral model of 2,5-hexanedione-induced neuropathy.

Sterman AB, Sheppard RC.

Neurobehav Toxicol Teratol. 1982 Sep-Oct;4(5):567-72.

PMID:
7177309
27.

The role of the neuronal cell body in neurotoxic injury.

Sterman AB.

Neurobehav Toxicol Teratol. 1982 Sep-Oct;4(5):493-4. No abstract available.

PMID:
6294540
28.

Cell body remodeling during dying-back axonopathy: DRG changes during advanced disease.

Sterman AB.

J Neuropathol Exp Neurol. 1982 Jul;41(4):400-11.

PMID:
6283036
29.

Luetic meningitis with gumma: clinical, radiographic, and neuropathologic features.

Kaplan JG, Sterman AB, Horoupian D, Leeds NE, Zimmerman RD, Gade R.

Neurology. 1981 Apr;31(4):464-7.

PMID:
7194439
31.

The acute sensory neuronopathy syndrome: a distinct clinical entity.

Sterman AB, Schaumburg HH, Asbury AK.

Ann Neurol. 1980 Apr;7(4):354-8.

PMID:
6246836
32.

The role of the cranial CT scan in municipal hospitals.

Sterman AB, Schaumburg HH.

Am J Public Health. 1980 Mar;70(3):268-70.

33.

Neurotoxic fragrance produces ceroid and myelin disease.

Spencer PS, Sterman AB, Horoupian DS, Foulds MM.

Science. 1979 May 11;204(4393):633-5.

PMID:
432669
34.

The acute sensory neuropathy syndrome: a distinct clinical entity.

Sterman AB, Schaumburg HH, Asbury AK.

Trans Am Neurol Assoc. 1979;104:22-5. No abstract available.

PMID:
233328
35.

Experimental myelin disease and ceroid accumulation produced by the fragrance compound acetyl ethyl tetramethyl tetralin.

Spencer PS, Sterman AB, Bischoff M, Horoupian D, Foster GV.

Trans Am Neurol Assoc. 1978;103:185-7. No abstract available.

PMID:
757054

Supplemental Content

Loading ...
Support Center